Searched for
SUN PHARMA BROKERAGES
Sensex rises over 200 points, Nifty above 24,000; Maruti Suzuki shares jump 3%Indian stock markets rebounded on Tuesday, with both Sensex and Nifty climbing approximately 0.4% after a dip in the previous session. The ...- PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- From Adani Green to Tata Tech: 50 companies swing back to profit in Q4 despite market turmoilIndian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...
- Buy, Sell or Hold: Citi maintains buy on Eicher Motors; Goldman Sachs retains buy on Max HealthcareBrokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian equity benchmarks closed modestly higher on Friday, with financial stocks leading the gains. The Nifty and Sensex edged up, though p...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...
- Stocks to buy in 2026 for long term: Varun Beverages, Sun Pharma among 5 stocks that could give 10-20% returnWe have collated a list of recommendations from top brokerage firms from ETNow and other sources
- Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...
- Buy, Sell or Hold: Motilal Oswal maintains buy on UTI AMC; Goldman Sachs downgrades Dr Reddy’s LaboratoriesBrokerages remain selective, with Motilal Oswal maintaining a bullish stance on UTI AMC and Aditya Birla Sun Life AMC, citing steady AUM gr...
- Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...
- Sun Pharma most exposed Indian company to Trump's new tariff threat, warns JefferiesIndian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...
- Brokerages up price targets on rising Sun, some point to cloudsMotilal Oswal has raised target price to Rs 900 and maintained a ‘buy’ rating on the back of improving traction in specialty products. Edel...
- Day after, Sun Pharma loses steam, but brokerages turn bullish on stockCLSA upgraded the target price of the stock to Rs 540 from Rs 520 earlier.
- Sun Pharma jumps 4% on solid Taro Pharma resultsTaro Pharma reported a 422 per cent year-on-year (YoY) jump in its net profit for the third quarter.
- Sun Pharma climbs 2% on USFDA approvalThe drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.
- USFDA clears Sun Pharma’s Halol plant, two years after it went under import banThe USFDA’s Establishment Inspection Report (EIR) comes days after the company received Voluntary Action Indicated (VAI) that indicated tha...
- Taro Pharma drops investment in wind power projectThe move had not gone down well with few brokerage houses who had raised concerns over the company investing in an unrelated business area.
Load More
